As mentioned, the critical role of CDK4 in the pathogenesis of PC, and the recent success of CDK4/6i in breast cancer, makes CDK4-inhibition a promising target for future therapeutics in the treatment of PC. Here, CDK4 is linked to pachyonychia congenita.